- Shares of EDAP TMS S.A. (EDAP -21.5%) drop on a 3x surge in volume. Earlier today, the FDA released its briefing documents for Wednesday's meeting of the Gastroenterology and Urology Devices Panel. The Committee will discuss the company's PMA for the use of Ablatherm HIFU as a treatment for prostate cancer.
- Investors appear to lack confidence in a positive vote. The agency's comments in the documents imply that reviewers have numerous questions/issues that need to be resolved regarding its clinical trial data.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs